Cholinesterase inhibitor utilization patterns: Just because it can be counted does not mean it counts

Journal of Managed Care Pharmacy

Volumn 14, Issue 5, 2008, Pages 462-464

  Starner, Catherine I ^a,b   Gleason, Patrick P ^a,b  

^a Prime Therapeutics LLC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG USE; DRUG UTILIZATION; DRUG WITHDRAWAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MEDICAID; NOTE; OPTIMAL DRUG DOSE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 48449087114     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.5.462     Document Type: Note

References (14)

1. Qaseem A, Snow V, Cross T, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-78.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2006, issue 1. Art, no.: CD005593. DOI: 10.1002/14651858.CD005593.
3. Mucha L, Wang S, Cuffel B, McRae T, Mark TL, del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm. 2008;14(5):451-61.
4. Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors. Rivastigmine versus donepezil in elderly patients with Alzheimers disease. Drugs Aging. 2005;22(8):695-707.
5. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 2005;11(3):231-39. Available at: www.amcp.org/data/jmcp/Research_231-239.pdf.
6. Singh G, Thomas SK, Lingala V. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc. 2005; 53(7):1269-70.
7. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care. 2001;10(2):42-45.
8. Pagano M, Gauvreau K. Principles of Biostatistics. Pacific Grove: Duxbury Press; 2000.
9. The theory of probability: Ion Saliu's paradox. Available at: http://about-probability.org/ion.htm. Accessed June 4, 2008.
10. Exelon patch (rivastigmine) [package insert]. Novartis Pharmaceuticals Corporation; East Hanover, NJ; 2007.
11. Aricept (donepezil) [package insert]. Eisai Inc.; Woodcliff Lake, NJ; 2006.
12. Razadyne ER (galantamine) [package insert]. Ortho-McNeil Neurologics, Inc.; Titusville, NJ; 2007.
13. Gruber-Baldini AL, Stuart B, Zuckerman IH, Simoni-Wastila L, Miller R. Treatment of dementia among community-dwelling and institutionalized Medicare beneficiaries. Effective Health Care Research Report No. 4. (Prepared by University of Maryland at Baltimore DEcIDE Center Under Contract No. HSA290200500391.) Rockville, MD: Agency for Healthcare Research and Quality. May 2008. Available at: http://effectivehealthcare.ahrq.gov/repFiles/DEcIDEDementia.pdf. Accessed June 5, 2008.
14. Curtiss FR. Does persistence with drugs for Alzheimer's disease matter? J Manag Care Pharm. 2005;11(3):260-62. Available at: www.amcp.org/ data/jmcp/Editorials_259-2611.pdf.